Exploration of orally available calpain inhibitors 2: Peptidyl hemiacetal derivatives

Journal of Medicinal Chemistry

Volumn 49, Issue 13, 2006, Pages 3926-3932

  Shirasaki, Yoshihisa ^a   Nakamura, Masayuki ^a   Yamaguchi, Masazumi ^a   Miyashita, Hiroyuki ^a,b   Sakai, Osamu ^a   Inoue, Jun ^a  

^a SENJU PHARMACEUTICAL CO LTD   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALPAIN; CALPASTATIN; N (4 FLUOROPHENYL)VALYLLEUCINAL; PEPTIDE DERIVATIVE; SJA 6017; SNJ 1715; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IC 50; MALE; NEUROPROTECTION; NONHUMAN; PROTEINASE INHIBITION; RAT; REPERFUSION INJURY; RETINA ISCHEMIA; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; CALPAIN; CELL LINE; DIPEPTIDES; DRUG STABILITY; HALF-LIFE; HUMANS; ISCHEMIA; MALE; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; RETINAL DISEASES; RETINAL GANGLION CELLS; SOLUBILITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIOUREA;

EID: 33745637434     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060157n     Document Type: Article

References (43)

1. (a) Ono, Y.; Sorimachi, H.; Suzuki, K. Pharmacology and toxicology of calcium-dependent protease. In Calpain; Wang, K. K. W., Yuen, P.-W., Eds.; Taylor & Francis: Philadelphia, 1999; pp 1-3.
2. (b) Huang, Y.; Wang, K. K. The calpain family and human disease. Trends Mol. Med. 2001, 7, 355-362.
3. (a) Wang, K. K. W.; Yuen, P.-W. Calpain inhibition: an overview of its therapeutic potential. Trench Pharmacol. Sci. 1994, 15, 412-419.
4. (b) Stracher, A. Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. Ann. N. Y. Acad. Sci. 1999, 884, 52-59.
5. Yuen, P.-W.; Wang, K. K. W. Therapeutic potential of calpain inhibitors in neurodegenerative disorders. Expert Opin. Invest. Drugs 1996, 5, 1291-1304.
6. Zatz, M.; Starling, A. Calpains and disease. N. Engl. J. Med. 2005, 352, 2413-2423.
7. (a) Donkor, I. O. A survey of calpain inhibitors. Curr. Med. Chem. 2000, 7, 1171-1188.
8. (b) Wells G. J.; Bihovsky, R. Calpain inhibitors as potential treatment for stroke and other neurodegenerative disease: recent trends and developments. Expert Opin. Ther. Pat. 1998, 8, 1707-1727
9. Leung, D.; Abbenante, G.; Fairlie, D. P. Protease inhibitors: current status and future prospects. J. Med. Chem. 2000, 43, 305-341.
10. (a) Sasaki, T.; Kikuchi, T.; Yumoto, N.; Yoshimura, N.; Murachi, T. Comparative specificity and kinetic studies on porcine calpain I and calpain II with naturally occurring peptides and synthetic fluorogenic substrates. J. Biol. Chem. 1984, 259, 12489-12494.
11. (b) Tompa, P.; Buzder-Lantos, P.; Tantos, A.; Farkas, A.; Szilágyi, A.; Bánóci, Z.; Hudecz, F.; Friedrich, P.; On the sequential determinants of calpain cleavage. J. Biol. Chem. 2004, 279, 20775-20785.
12. Iqbal, M.; Messina, P. A.; Freed, B.; Das, M.; Chatterjee, S.; Tripathy, R.; Tao, M.; Josef, K. A.; Dembofsky, B.; Dunn, D.; Griffith, E.; Siman, R.; Senadhi, S. E.; Biazzo, W.; Bozyczko-Coyne, D.; Meyer, S. L.; Ator, M. A.; Bihovsky, R. Subsite requirements for peptide aldehyde inhibitors of human calpain I. Bioorg. Med. Chem. Lett. 1997, 7, 539-544.
13. Moldoveanu, T.; Campbell, R. L.; Currier, D.; Davis, P. L. Crystal Structures of calpain-E64 and -leupeptin inhibitor complexes reveal mobile loops gating the active site. J. Mol. Biol. 2004, 343, 1313-1326.
14. Aoyagi, T.; Takeuchi, T.; Matsuzaki, A.; Kawamura, K.; Kondo, S. Leupeptines, new protease inhibitors from Actinomycetes. J. Antibiot. 1969, 22, 283-286.
15. Sasaki, T.; Kishi, M.; Saito, M.; Tanaka, T.; Higuchi, N.; Kominami, N.; Katunuma, N.; Murachi, T. Inhibitory effect of di- and tripeptidyl aldehydes on calpains and cathepsins. J. Enzyme Inhib. 1990, 3, 195-201.
16. Mehdi, S. Cell-penetrating inhibitors of calpain. Trends Biochem. Sci. 1991, 16, 150-153.
17. Li, Z.; Ortega-Vilain, A.; Patil, G. S.; Chu, D.; Foreman, J. E. Novel peptidyl α-keto amide inhibitors of calpains and other cysteine proteases. J. Med. Chem. 1996, 39, 4089-4098.
18. Lubisch, W.; Beckenbach, E.; Bopp, S.; Hofmann, H. P.; Kartal, A.; Kastei, C.; Lindner, T.; Metz-Garrecht, M.; Reeb, J.; Regner, F.; Vierling, M.; Möller, A. Benzoylalanine-derived ketoamides carrying vinylbenzul amino residues: Discovery of potent water-soluble calpain inhibitors with oral bioavailability J. Med. Chem. 2003, 46, 2404-2412.
19. (a) Fukiage, C.; Azuma, M.; Nakamura, Y.; Tamada, Y.; Nakamura, M.; Shearer, T. R. SJA6017, A newly synthesized peptide aldehyde inhibitor of calpain: amelioration of cataract in cultured rat lenses. Biochim. Biophys. Acta 1997, 1361, 304-312.
20. (b) Inoue, J.; Nakamura, M.; Cui, Y.; Sakai, Y.; Sakai, O.; Hill, J. R.; Wang, K. K. W.; Yuen, P.-W. Structure-activity relationship study and drug profile of N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (SJA6017) as a potent calpain inhibitor. J. Med. Chem. 2003, 46, 868-871.
21. Lee, K. S.; Franks, S.; Vanderklish, P.; Arai, A.; Lynch, G. Inhibition of proteolysis protects hippocampal neurons from ischemia. Proc. Natl. Acad. Sci. U.S.A. 1991, 57, 7233-7237.
22. Rami, A.; Krieglstein, J. Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia and ischemia in vivo. Brain Res. 1993, 609, 67-70.
23. (a) Hong, S.-C.; Goto, Y.; Lanzino, G.; Saleau, S.; Kassel N. F.; Lee, K. S. Neuroprotection with a calpain inhibitor in a model of focal cerebral ischemia. Stroke 1994, 25, 663-669.
24. (b) Markgraf, C. G.; Velayo, N. L.; Johnson, M. P.; McCarty, D. R.; Medhi, S.; Koehl, J. R.; Chmielewski, P. A.; Linnik, M. D. Six-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats. Stroke 1998, 29, 152-158.
25. Bartus, R. T.; Hayward, N. J.; Elliott, P. J.; Sawyer, S. D.; Baker, K. L.; Dean, R. L.; Akiyama, A.; Straub, J. A.; Harbeson, S. L.; Li, Z.; Powers, J. Calpain inhibitor AK-295 protects neurons from focal brain damage. Stroke 1994, 25, 2265-2270.
26. Neuhof, W.; Götte, O.; Trumbeckaite, S.; Attenberger, M.; Kuzkaya, N.; Gellerish, F.; Möller, A.; Lubisch, W.; Speth, M.; Tillmanns, H.; Neuhof, H.; A novel water-soluble and cell-permeable calpain inhibitor protects myocardial and mitochondrial function in postischemic reperfusion. Biol. Chem. 2003, 384, 1597-1603.
27. Nath, R.; Davis, M.; Probert, A. W.; Kupina, N. C.; Ren, X., Schielke G. P.; Wang, K. K. Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells. Biochem. Biophys. Res. Commun. 2000, 274, 16-21.
28. Sakamoto, Y.; Nakajima, T.; Fukiage, C.; Sakai, O.; Yoshida, Y.; Azuma, M.; Shearer, T. R. Involvement of calpain isoforms in ischemia-reperfusion injury in rat retina. Curr. Eye. Res. 2000, 21, 571-580.
29. Sasaki, H.; Yamamura, K.; Mukai, T.; Nishida, K.; Nakamura, J.; Nakashima, M.; Ichikawa, M. Enhancement of ocular drug penetration. Crit. Rev. Ther. Drug Carrier Syst. 1999, 16, 85-146.
30. Sakamoto, Y. Unpublished results.
31. (a) Nakamura, M.; Inoue, J. Exploration of peptidyl hydrazones as water-soluble calpain inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 1603-1606.
32. (b) Shirasaki, Y.; Miyashita, H.; Yamaguchi, M.; Inoue, J.; Nakamura, M. Exploration of orally available calpain inhibitors: peptidyl α-ketoamides containing an amphiphile at P3 site. Bioorg. Med. Chem. 2005, 13, 4473-4484.
33. Nakamura, M.; Yamaguchi, M.; Sakai, O.; Inoue, J. Exploration of cornea permeable calpain inhibitors as anticataract agents. Bioorg. Med. Chem. 2003, 11, 1371-1379.
34. Altmann, E.; Betschart, C.; Gohda, K.; Horiuchi, M.; Lattmann, R.; Missbach, M.; Sakaki, J.; Takai, M.; Teno, N.; Cowen, S. D.; Greenspan, P. D.; McQuire, L. W.; Tommasi, R. A.; Van D., John H. PCT Int. Appl. WO9924460, 1999.
35. (a) Angelastro, M. R.; Mehdi, S.; Burkhart, J. P.; Peet, N. P.; Bey, P. α-Diketone and α-keto ester derivatives of N-protected amino acids and peptides as novel inhibitors of cysteine and serine proteinases. J. Med. Chem. 1990, 33, 11-13.
36. (b) Mehdi, S. Synthetic and naturally occurring protease inhibitors containing an electrophilic carbonyl group. Bioorg. Chem. 1993, 21, 249-259.
37. Otto, H.-H.; Schirmeister, T. Cysteine protease and their inhibitors. Chem. Rev. 1997, 97, 133-171.
38. Peet N. P.; Kim, H. O.; Marquart, A. L.; Angelastro, M. R.; Nieduzak, T. R.; White, J. N.; Friedrich, D.; Flynn, G. A.; Webster, M. E.; Vaz, R. J.; Linnik, M. D.; Koehl, J. R.; Mehdi, S.; Bey, P.; Emary, B.; Hwang K. K. Hydroxyoxazolidines as alpha-aminoacetaldehyde equivalents: novel inhibitors of calpain. Bioorg. Med. Chem. Lett. 1999, 9, 2365-2370.
39. Li, Z.; Patil, G. S.; Golubski, Z. E.; Hori, H.; Tehrani, K.; Foreman, J. E.; Eveleth, D. D.; Bartus, R. T.; Powers, J. C. Peptide α-keto ester, peptide α-keto amide and peptide α-keto acid inhibitors of calpains and other cysteine proteases. J. Med. Chem. 1993, 36, 3472-3480.
40. Nakamura, M.; Miyasita, H.; Yamaguchi, M.; Shirasaki, Y.; Nakamura, Y.; Inoue, J. Novel 6-hydroxy-3-morpholinones as cornea permeable inhibitors. Bioorg. Med. Chem. 2003, 11, 5449-5460.
41. van de Waterbeemed, H.; Smith, D. A.; Beaumont, K.; Walker, D. K. Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem. 2001, 44, 1313-1334.
42. Ando, R.; Sasaki, T.; Masuda, H.; Inakoshi, N.; Jikihara, T.; Fujimura, Y.; Niwa, T.; Yoshii, N.; Tabata, R. PCT Int. Appl. WO9625408, 1998.
43. Buroker-Kilgore, M.; Wang, K. K. W. A coomassie brilliant blue G-250-based colorimetric assay for measuring activity of calpain and other proteases. Anal. Biochem. 1993, 208, 387-392.